RET and medullary thyroid gland carcinoma: One phase 1-2 study 156 demonstrated the efficacy and safety of pralsetinib in patients with medullary thyroid cancer, with response rates of 71% in treatment-naive patients, 60% in those previously treated with cabozantinib and/or vandetanib, and 89% in patients with RET fusions.